TrialBMC cancer2026

Surufatinib plus tislelizumab as later-line therapy for metastatic colorectal cancer: a single-arm, phase II trial.

Huijun Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.